Related Experiment Video
Updated: Jul 28, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Hepatitis C, B, D, and A: contrasting features and liver function abnormalities in heroin addicts
1Veract, Inc., West Covina, CA 91790, USA.
Insights
Hepatitis C virus (HCV) significantly impacts intravenous heroin addicts (IVHAs), often leading to chronic liver disease and extra-hepatic manifestations. Early diagnosis and antiviral therapy in the active stage are crucial for better outcomes.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Intravenous heroin addicts (IVHAs) have a high prevalence of Hepatitis C Virus (HCV) infection, exceeding 90%.
- While other hepatitis viruses (A, B, D, G) are less significant, active Hepatitis B can present similarly to chronic HCV.
- The clinical course for both HCV and active Hepatitis B can be long-term, spanning over three decades.
Purpose of the Study:
- To highlight the significant impact of HCV in IVHAs.
- To emphasize the importance of staging liver disease (active, cirrhosis, liver failure).
- To underscore the potential for antiviral therapy in the early, active stage of HCV.
Main Methods:
- Clinical observation and classification of patients based on disease stage.
- Monitoring of liver enzymes (ALT and AST) to identify active disease.
- Review of extra-hepatic manifestations associated with HCV.
Main Results:
- HCV is the predominant hepatitis virus among IVHAs.
- Elevated ALT and AST levels are indicative of the active, early stage of the disease.
- HCV presents with numerous extra-hepatic manifestations, suggesting a systemic 'HCV syndrome'.
Conclusions:
- HCV infection is a major health issue for IVHAs, often leading to chronic liver damage.
- Early-stage intervention with antiviral therapy offers the best chance for successful treatment.
- HCV should be recognized as a syndrome with widespread systemic effects beyond the liver.
Abstract:
Over 90% of intravenous heroin addicts (IVHAs) carry the hepatitis C virus (HCV). The other hepatitis viruses, A, B, D, and G are relatively unimportant in IVHAs compared to HCV although active hepatitis B may demonstrate a chronic, degenerative course identical to that of HCV. The clinical course of HCV and active hepatitis B may span three or more decades. It is helpful to classify patients as in the active, cirrhosis, or liver failure stages. Only in the active, early stage are the liver enzymes, ALT and AST, likely to be elevated. It is this stage that will most likely respond to antiviral therapy. HCV has so many extra-hepatic manifestations including immune suppression, collagen diseases, and possibly lymphoma and leukemia that the disease is best termed HCV syndrome rather than simple hepatitis.
More Related Videos
10:25"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
Published on: February 19, 2019
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Hepatitis
Viral Hepatitis I: Introduction
Cirrhosis I: Introduction
Cirrhosis II: Pathophysiology